Dusty Majumdar is the CEO of PredxBio, a precision pathology company leveraging AI and spatial biology to transform cancer diagnostics and therapeutics. With over two decades of leadership experience in precision healthcare, he has held senior roles at the American Society of Clinical Oncology, IBM, Exact Sciences, and GE Healthcare. Dusty has spoken at numerous forums, including The Economist War on Cancer and a MIT plenary lecture on AI in healthcare.

Despite recent advances in cancer research, early detection and effective treatment remain major challenges. Traditional diagnostic tools often fail to fully capture the complex biological interactions driving tumor growth and therapy resistance. How can emerging technologies like AI and spatial biology help personalize cancer care and improve patient outcomes?

Spatial biology and AI can decode the tumor microenvironment at a much deeper level than genomics alone. By analyzing how cells organize and communicate within tumors, this approach can predict therapy responses with over 90% accuracy. Oncology, genomics, and AI-driven healthcare leader Dusty Majumdar emphasizes the importance of integrating multi-omic data, such as proteomics, transcriptomics, and metabolomics, to personalize treatment strategies. He envisions a future where virtual clinical trials drastically reduce development time and costs while improving trial success rates.

Tune in to this episode of Transaction Healthcare as host Zak Eisenberg chats with Dusty Majumdar, CEO of PredxBio, about using AI and spatial biology to transform oncology care. Dusty talks about liquid biopsy limitations, the role of regulatory bodies like the FDA, and the evolution of AI in healthcare.